P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?

Autor: Koutsougianni F; Department of Pharmacology, Faculty of Medicine, Health Sciences School, University of Thessaly, Larissa, Greece., Alexopoulou D; Department of Pharmacology, Faculty of Medicine, Health Sciences School, University of Thessaly, Larissa, Greece., Uvez A; Department of Histology and Embryology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34500 Istanbul, Turkey., Lamprianidou A; Department of Pharmacology, Faculty of Medicine, Health Sciences School, University of Thessaly, Larissa, Greece., Sereti E; Dept of Translational Medicine, Medical Faculty, Lund University and Center for Molecular Pathology, Skäne University Hospital, Jan Waldenströms gata 59, SE 205 02 Malmö, Sweden., Tsimplouli C; Department of Pharmacology, Faculty of Medicine, Health Sciences School, University of Thessaly, Larissa, Greece., Ilkay Armutak E; Department of Histology and Embryology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34500 Istanbul, Turkey., Dimas K; Department of Pharmacology, Faculty of Medicine, Health Sciences School, University of Thessaly, Larissa, Greece. Electronic address: kdimas@uth.gr.
Jazyk: angličtina
Zdroj: Biochemical pharmacology [Biochem Pharmacol] 2023 Apr; Vol. 210, pp. 115488. Date of Electronic Publication: 2023 Mar 07.
DOI: 10.1016/j.bcp.2023.115488
Abstrakt: The 90 kDa ribosomal S6 kinase (RSK) family of proteins is a group of highly conserved Ser/Thr kinases. They are downstream effectors of the Ras/ERK/MAPK signaling cascade. ERK1/2 activation directly results in the phosphorylation of RSKs, which further, through interaction with a variety of different downstream substrates, activate various signaling events. In this context, they have been shown to mediate diverse cellular processes like cell survival, growth, proliferation, EMT, invasion, and metastasis. Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. This review aims to present the most recent advances in the field of RSK signaling that have occurred, such as biological insights, function, and mechanisms associated with carcinogenesis. We additionally present and discuss the recent advances but also the limitations in the development of pharmacological inhibitors of RSKs, in the context of the use of these kinases as putative, more efficient targets for novel anticancer therapeutic approaches.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: KONSTANTINOS-DIMAS reports a relationship with General Secretariat for Research and Technology and EU that includes: funding grants.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: